Delivering a robust inorganic growth strategy is critical for companies to thrive in the competitive landscape of the biopharma industry. However, we often observe firms to have two separate and unaligned teams–the M&A and alliances teams that deliver the same set of strategic objectives, but too often get in each other's way. We believe building a multi- disciplined team that manages both alliances and M&A integrations can help drive the best result of your inorganic business growth.
In this 45-minute session, participants will:
Carlos is an M&A integration expert and founding Partner of Beyond the Deal. He has over twenty years of integration, organizational change and project management experience, and has supported acquisitions and integrations across industry sectors and countries across the globe. He advises businesses on corporate and acquisition strategies, design of post-deal operating models, operational performance reviews, and helps deliver programs of major business restructuring and improvement.
Prior to Beyond the Deal, Carlos worked with PwC and Accenture designing and managing integration, restructuring and other business improvement initiatives. Alongside his client work, Carlos is also a Non-Executive Director of IPR, an international energy firm based in the US. A published author on leadership in M&A, Carlos regularly writes and speaks on key success conditions and best practice in acquisition and integration at conferences and other events in the US and Europe. Carlos holds a Masters in Chemical Engineering from Imperial College, London.
David Olsson is a BTD Partner with over 15 years of experience in corporate development and integration in mid-market private, corporate and PE-backed enterprises across UK and EMEA. As a practitioner David has formulated strategy, originated deals and managed the change via separation and integration. As a consultant he has advised, coached, trained a range of clients from private equity backed portfolios to FTSE 100 companies. David's background includes operational roles in IT and Finance.
Nick is a Senior executive catalyzing major organizational transformation for global clients. Proven ability to orchestrate international teams. Extensive expertise capitalizing on technical and business-model innovation through organizational transformation, strategic alliances, joint ventures, outsourcing, and M&A. Industries served include oil & gas, paper manufacturing, insurance, pharmaceuticals, bus and rail transit, and theme parks. He is a leader of internal organizational and personnel-development initiatives, with particular strength in consultant and team training design, implementation and delivery.
Nick holds an MBA and a Doctoral Fellowship in Business Economics from Harvard University and a BSc in Chemical Engineering from Rensselaer Polytechnic Institute.
Sally has over 20 years' experience accelerating growth and overcoming leadership challenges as an Executive Change Mentor. She designs and delivers leadership development programs that equip clients to make successful change.
Vice President, Alliance and Integration Management (AIM)
Steve has responsibility for AstraZeneca's alliance and integration management (AIM) strategy and execution capabilities. Steve's team leads the integration of all major acquisitions, the transitions for divestments, and management of key alliances for AZ. Steve joined AZ in January 2015, after spending 26 years at Eli Lilly and Company where he was a founding member of Lilly's Office of Alliance Management. Steve is a well published author in Pharmaceutical Executive, PLG's Business Development & Licensing Journal, and Strategic Alliance Quarterly and is a board member and treasurer of the Association of Strategic Alliance Professionals.